Amphastar Pharmaceuticals (AMPH) Cost of Revenue (2013 - 2026)

Amphastar Pharmaceuticals has reported Cost of Revenue for 14 years, with the latest figure at $90.4 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 2.85% year-over-year to $90.4 million in Q2 2026; TTM through Jun 2026 was $381.9 million, a 5.4% increase from a year earlier, with the FY2025 full-year figure at $363.8 million, up 1.6% from the prior year.
• Cost of Revenue was $90.4 million for Q2 2026 at Amphastar Pharmaceuticals, down from $100.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $100.8 million in Q1 2026, with the low at $60.1 million in Q2 2022.
• Average Cost of Revenue over 5 years is $80.9 million, with a median of $83.6 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue climbed 28.36% in 2023, then decreased 2.44% in 2025.
• Over 5 years, Cost of Revenue stood at $63.9 million in 2022, then increased by 28.36% to $82.0 million in 2023, then gained by 21.85% to $99.9 million in 2024, then dropped by 2.44% to $97.4 million in 2025, then decreased by 7.19% to $90.4 million in 2026.
• The last three Cost of Revenue figures came in at $90.4 million (Q2 2026), $100.8 million (Q1 2026), and $97.4 million (Q4 2025), per Business Quant data.